Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW685698X Morning · 1 trial · 1 indication
Mean change from baseline in daily trough (pre study treatment and pre bronchodilator) PEF during the 28 day treatment period with GW685698X 100mcg once daily in the morning compared with GW685698X 100mcg once daily in the evening by inhalation via DISKHALER.
| Arm | Type | Description |
|---|---|---|
| GW685698X (fluticasone furoate) 100mcg Morning | EXPERIMENTAL | - |
| GW685698X (fluticasone furoate) 100mcg Evening | EXPERIMENTAL | - |
| GW685698X (fluticasone furoate) 250mcg Evening | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| GW685698X (fluticasone furoate) 100mcg Morning | DRUG | GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days |
| GW685698X (fluticasone furoate) 100mcg Evening | DRUG | GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days |
| GW685698X (fluticasone furoate) 250mcg Evening | DRUG | GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days |
| Placebo | DRUG | Placebo inhaled twice daily (morning and evening) for 28 days |
Inclusion Criteria: * Outpatients aged between 16- 65 years. * Male and female; female subjects must be non-child bearing potential or of childbearing potenetial with negative pregnancy test and willing to use acceptable contraceptive methods * Documented clinical history of persistent asthma first...
GW685698X Morning is an investigational small molecule being studied for the treatment of persistent bronchial asthma. It is administered once daily via the DISKHALER device. The drug is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
GW685698X Morning is a small molecule developed for asthma, but its specific molecular target has not been disclosed in available information. The drug is being evaluated for its efficacy and safety in patients with persistent bronchial asthma through clinical trials.
GW685698X Morning is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with asthma.
GW685698X Morning is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for the treatment of persistent bronchial asthma.
GW685698X Morning has one completed Phase 2 clinical trial, NCT01499446, which enrolled 669 participants with persistent bronchial asthma. The study was randomized, double-blind, and placebo-controlled, evaluating the drug administered once daily in the morning or evening for 28 days.
GW685698X Morning is a specific dosing regimen of the investigational drug GW685698X, referring to administration in the morning. The clinical trial NCT01499446 compared morning and evening dosing of GW685698X to assess the impact of dosing time on efficacy and safety in asthma patients.